

# EGID SEMINAR

January 26<sup>th</sup>, 2024 from 11.00 am to 12.00 pm



Pr David J. Hodson

Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM),  
NIHR Oxford Biomedical Research Centre, Churchill Hospital,  
Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

## Understanding GLP-1 and GIP receptor expression and signalling in the brain and periphery

Glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulintropic polypeptide receptor (GIPR) have emerged as major drug targets for the treatment of type 2 diabetes and obesity. For example, drugs that target GLP1R and/or GIPR show profound effects on glucose levels and food intake. Despite this, we still have limited knowledge of where GLP1R and GIPR are expressed in the body, which is holding back development of even more effective drugs. In the current presentation, I will introduce new technologies to visualize and interrogate GLP1R and GIPR expression with single cell and single molecule resolution.

I will also discuss how these studies have led to new understanding of GLP1R and GIPR biology, with relevance for type 2 diabetes and obesity therapy, as well as ongoing clinical trials on neurodegenerative and inflammatory disease.

UFR3S - Pôle recherche - Salle des Congrès  
1 place de Verdun, 59 045 Lille CEDEX

